|| List of recent Arm-related patents
| Method of provisioning a cloud-based render farm|
This invention relates to a method of provisioning a cloud-based render farm. Cloud- based render farms are relatively difficult to establish and require skilled it personnel to create and operate.
| Pharmacy tracking system with automatically-entered customer transaction information|
A method of conducting a transaction involving transfer of a filled prescription order from a pharmacy to a customer. The method includes detecting that the filled prescription order is available for transfer from the pharmacy to the customer.
| Medication management system|
The medication management system is divided into hospital server, pharmacy server, and patient mobile device. The hospital server and pharmacy server contain all patient active and inactive medication profiles.
| Cross-dipole antenna configurations|
An apparatus has an improved antenna pattern for a cross dipole antenna. Such antennas desirably have an omnidirectional antenna pattern.
| Trailer theft detection and alarm|
An electronic control unit used in, e.g., a towing vehicle includes a processing device configured to determine an initial electrical load of a trailer system, detect changes in the electrical load, and generate an alarm signal if the electrical load is substantially different from the initial electrical load. A method includes determining an electrical load of a trailer system prior to arming a vehicle alarm system, detecting changes in the electrical load after arming the vehicle alarm system, and triggering the alarm system if the electrical load is substantially different from the electrical load determined prior to arming the vehicle alarm system..
| Sagittal angle screw with integral shank and receiver|
A spinal bone screw has a receiver with upstanding arms forming a channel for receiving a longitudinal connecting member, such as a rod, the receiver being integral with a threaded shank. The receiver further includes inner surfaces in sliding engagement with an insert, the insert having a seating surface for the rod.
| Suture passer with radiused upper jaw|
Described herein are suture passers that may be used for repair of the meniscus of the knee. These suture passers typically include an elongate body having a pair of arms.
| Needle safety device|
Described is a needle safety device comprising a needle hub, a needle coupled to the needle hub and having a distal tip; a needle shield telescopically coupled to the needle hub, the needle shield, a locking element including latch arms adapted to engage the needle hub and engagement elements adapted to engage the needle shield. When the needle shield is in a first axial position (pa1) relative to the needle hub, the needle shield covers the distal tip of the needle and the engagement elements of the locking element engage the needle shield.
| Compression garment apparatus having baseline pressure|
A compression garment apparatus including a compression garment and a pressurizer. The pressurizer intermittently pressurizes a therapeutic bladder on the compression garment and maintains a baseline pressure in the therapeutic bladder to maintain the therapeutic bladder in position with respect to a target compression zone on a body part on which the garment is worn.
| Carpal tunnel relief device|
A carpal tunnel relief device is configured for adhesive application to a skin area above the median nerve of the distal forearm, wrist or a palm of the subject and includes a middle curved portion shaped to pull the skin and surrounding soft tissues away from the median nerve therefore releasing compression of the median nerve and pain associated with carpal tunnel syndrome. Resilient flexible member may be incorporated with the device or inserted in a pocket of a flexible fabric after its adhesion to the skin..
| System and method for determining a vital sign of a subject|
The present invention relates to a system for determining a vital sign of a subject by which the likelihood of generating and outputting false alarms is reduced. The system comprises a vital sign processor that processes said vital sign information signal measured by a sensor attached to a subject to obtain a vital sign of said subject, an image analysis unit that detects motion of a marker attached to said sensor from image data obtained by an imaging unit from at least an imaging region containing said sensor, and an alarm unit that generates and outputs an alarm signal based on the measured vital sign information signal and/or obtained vital sign and on the detected motion of said marker..
| Preparation of fingolimod and its salts|
The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.. .
| Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof|
Methods of making saxagliptin, pharmaceutically acceptable salts and hydrates thereof and intermediates thereof.. .
| Biphenyl derivatives|
Wherein r1, r2, r3, r4, r5, r6, r7, w, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma..
| Tricyclic antibiotics|
Compounds of formula (i), wherein a1 represents —o—, —s— or —ch2—; a2 represents —ch2— or —o—; a3 represents c3-c8-cycloalkylene; saturated or unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, which group a3 is unsubstituted or substituted; a4 represents c1-c4alkylene, —c(=0)-; g represents aryl or heteroaryl, which is unsubstituted or substituted; x1 represents a nitrogen atom or cr1; r1 represents a hydrogen atom or a halogen atom; r1 represents a hydrogen atom; m is 0 or 1; n is 1; the —(ch2)n— group is unsubstituted or substituted; p is 0 or 1; or pharmaceutically acceptable salts thereof are valuable for use as a medicament for the treatment of bacterial infections.. .
| Phenoxyethoxy compounds|
Or a pharmaceutically acceptable salt thereof.. .
| Delayed release, oral dosage compositions that contain amorphous cddo-me|
Pharmaceutical formulations exhibit a desirably low cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl..
| Pharmaceutical composition on the basis of nanomicelles containing epigallocatechin gallate and a method of administration thereof to treat atopic dermatitis, crohn's disease, adenomyosis, and hyperplastic diseases of the prostate gland|
The invention relates to pharmacy. It is an object of the present invention to produce nanomicellar structures containing egcg and achieving a positive result consisting in increasing bioavailability in peroral administration.
| Methods and compositions for predicting response to eribulin|
The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.. .
| Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation|
The present invention relates to the use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine or a pharmaceutically acceptable salt thereof for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation.. .
| Methods of treating cognitive dysfunction by modulating brain energy metabolism|
Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.. .
| Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases|
The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.. .
| Desferrithiocin polyether analogues|
Or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.. .
| Topical ophthalmological pharmaceutical composition containing sorafenib|
The present invention relates to topical ophthalmological pharmaceutical compositions containing sorafenib or a pharmaceutically acceptable salt thereof or a polymorph, hydrate or solvate thereof and its process of preparation and its use for treating ophthalmological disorders.. .
| Chromene modulators of chemokine receptor activity|
Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
| Scriptaid isosteres and their use in therapy|
Or a pharmaceutically acceptable salt thereof. The compounds are useful in therapy..
| Imidazopyridyl compounds as aldosterone synthase inhibitors|
This invention relates to imidazopyridyl compounds of the structural formula: i or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase.
| Stable pharmaceutical formulations of methylnaltrexone|
Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided..
| Buprenorphine for the treatment of acute suicidality|
Methods and compositions for treating acute suicidality by administration of buprenorphine are disclosed herein. An exemplary method is effected by administering to a subject determined as having acute suicidality a first therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, whereby the administration is ceased once the subject is no longer determined as having acute suicidality.
| Quinazoline derivatives as kinases inhibitors and methods of use thereof|
The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions..
| Therapeutic compounds and uses thereof|
Described herein are compounds of formula (i)-(iii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
| Hydrazide containing nuclear transport modulators and uses thereof|
Or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula i, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with crm1 activity..
| Pyridine derivatives|
The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
| Substituted bicyclic heteroaryl compounds|
Disclosed are azaindazole compounds of formula (i): or a pharmaceutically acceptable salt thereof, wherein: x is o and y is n; or x is s and y is ch; z is cr2 or n; q is a heteroaryl; and r1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one cyp17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds..
| Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer|
Wherein the wedged bonds, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, x and y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula i, by reacting formula i with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula i, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier..
| Novel quinoxaline inhibitors of pi3k|
The invention provides methods that relate to a novel therapeutic strategy for the treatment of cancer and inflammatory diseases. In particular, the method comprises administration of a compound of formula i, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient..
| Therapeutic compounds and uses thereof|
Described herein are compounds of formula (i) or formula (vi), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i) or formula (vi) and pharmaceutical compositions thereof that are mucus penetrating.
| Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders|
Or a pharmaceutically acceptable salt or solvate thereof, where r1-r3 and y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.. .
| Inhibitors of the renal outer medullary potassium channel|
And pharmaceutically acceptable salts thereof which are inhibitors of the renal outer medullary potassium (romk) channel (kir1.1). The compounds of formula i are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure..
| Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them|
Or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid β production, especially an effect of inhibiting bace1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins.. .
| 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh|
The invention is directed to a compound of formula (i) or a pharmaceutically acceptable salt thereof, wherein r1-r6 are defined herein. The invention is also directed to compositions containing a compound of formula (i) and to the use of such compounds in the inhibition of mutant idh proteins having a neomorphic activity.
| Azabenzimidazole compounds|
Or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.. .
| Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same|
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to gaba function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds..
| Biaryl heterocycle substituted oxazolidinone antibacterial agents|
The present invention relates to a biaryl heterocycle substituted oxazolidinone antibacterials shown by general formula (i), a pharmaceutically acceptable salt thereof, an isomer or a prodrug thereof, wherein r1, r2, r3, r4, r5, a and b are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound in the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases..
| Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives|
Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating nsclc..
| Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists|
The present invention relates to compounds of formula (i), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iglur receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iglur receptors.. .
| Agent for preventing or treating htlv-i associated myelopathy|
The present invention provides a prophylactic or therapeutic agent for ham, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a ham-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient..
| 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases|
The present invention relates to 5′-substituted nucleoside derivatives of formula (i): (i) and pharmaceutically acceptable salts thereof, wherein b, x, y, z, r1, r2, r3 and r3′ are as defined herein. The present invention also relates to compositions comprising at least one 5′-substituted nucleoside derivative, and methods of using the 5′-substituted nucleoside derivatives for treating or preventing hcv infection in a patient..
| Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent|
An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne.
| Anti-cancer pharmaceutical composition|
Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-d-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients.
| Pharmaceutical composition having activity of anticancer|
Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and a glycolysis inhibitor, particularly, 2-deoxy-d-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients.
| The use of hcv immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis|
The present invention provides the use of hepatitis c virus immunogenic peptides or derivative thereof in the manufacture of a pharmaceutical for preventing or treating arthritis, wherein the peptide or derivative thereof is a peptide represented by formula i or pharmaceutically acceptable salt or ester thereof. The present invention further provides a method for treating arthritis, including administering a pharmaceutical containing therapeutically effective amount of said peptide or derivative thereof to a patient.
| Interactive personal surveillance and security (ipss) systems and methods|
Embodiments relating to an interactive personal surveillance and security (ipss) system are provided for one or more users carrying one or more respective wireless personal communication devices (wcds) that are capable of capturing and sending surveillance information (e.g., video, images, audio, sensor data, etc.) to one or more remotely located servers (rlss). From the information, the rlss can identify and secure dangerous environments, encounters, etc., and log events or take other actions.
| Garment with support back-wing|
The present invention includes a garment, such as a bra or a shaper, having regions of differential elasticity. For example, a bra includes: two cups located at a front side of the bra; and a backwing comprising a plurality of regions having differential elasticity.
| Female electrical connector with terminal arm extension protection|
A female electric connector includes a terminal body with a plurality of terminal arms. The terminal arms extend from the terminal body around a terminal axis.
| Externally serviceable it memory dimms for server/tower enclosures|
An electronic component carrier and method for mounting the electronic component to a circuit board includes a frame including a header having opposing attachment arms extending outwardly therefrom for seating an electronic component within the frame. A latching mechanism of the frame includes latching members at a distal end of each of the attachment arms for releaseably seating the electronic component between the attachment members.